1. Home
  2. HRMY vs OPRA Comparison

HRMY vs OPRA Comparison

Compare HRMY & OPRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • OPRA
  • Stock Information
  • Founded
  • HRMY 2017
  • OPRA 1996
  • Country
  • HRMY United States
  • OPRA Norway
  • Employees
  • HRMY N/A
  • OPRA N/A
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • OPRA Computer Software: Prepackaged Software
  • Sector
  • HRMY Health Care
  • OPRA Technology
  • Exchange
  • HRMY Nasdaq
  • OPRA Nasdaq
  • Market Cap
  • HRMY 2.0B
  • OPRA 1.6B
  • IPO Year
  • HRMY 2020
  • OPRA 2018
  • Fundamental
  • Price
  • HRMY $35.31
  • OPRA $18.18
  • Analyst Decision
  • HRMY Strong Buy
  • OPRA Strong Buy
  • Analyst Count
  • HRMY 9
  • OPRA 5
  • Target Price
  • HRMY $54.22
  • OPRA $24.90
  • AVG Volume (30 Days)
  • HRMY 738.5K
  • OPRA 413.1K
  • Earning Date
  • HRMY 05-06-2025
  • OPRA 04-28-2025
  • Dividend Yield
  • HRMY N/A
  • OPRA 4.40%
  • EPS Growth
  • HRMY 13.13
  • OPRA N/A
  • EPS
  • HRMY 2.62
  • OPRA 0.93
  • Revenue
  • HRMY $744,852,000.00
  • OPRA $521,494,000.00
  • Revenue This Year
  • HRMY $20.35
  • OPRA $22.54
  • Revenue Next Year
  • HRMY $17.42
  • OPRA $15.85
  • P/E Ratio
  • HRMY $13.46
  • OPRA $19.49
  • Revenue Growth
  • HRMY 20.62
  • OPRA 26.68
  • 52 Week Low
  • HRMY $26.47
  • OPRA $10.11
  • 52 Week High
  • HRMY $41.61
  • OPRA $22.50
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 61.62
  • OPRA 57.81
  • Support Level
  • HRMY $33.47
  • OPRA $17.66
  • Resistance Level
  • HRMY $35.35
  • OPRA $18.42
  • Average True Range (ATR)
  • HRMY 1.09
  • OPRA 0.59
  • MACD
  • HRMY -0.01
  • OPRA -0.04
  • Stochastic Oscillator
  • HRMY 70.34
  • OPRA 54.24

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About OPRA Opera Limited

Opera Ltd is a world-wide internet brand with a large, engaged, and growing base. It offers users products and services that include a variety of PC and mobile browsers, Opera Gaming portals and development tools, Opera News content recommendation products, and a number of e-commerce products and services. Its browser's features include tabbed browsing, data savings, PC/mobile sync, and numerous features focused on privacy and security, including ad blocking and a built-in VPN. Its browser products include Opera Mini, Opera Browser for Android and iOS, Opera for Computers, Opera GX and Opera GX Mobile, separate browsers tailored for gamers. Geographically, the company generates maximum revenue from the United States, followed by Singapore, Nigeria, Russia, and other locations.

Share on Social Networks: